Insmed Inc (INSM.OQ)
INSM.OQ on NASDAQ Stock Exchange Capital Market
10.90USD
10:57am EDT
10.90USD
10:57am EDT
Price Change (% chg)
$-0.21 (-1.89%)
$-0.21 (-1.89%)
Prev Close
$11.11
$11.11
Open
$11.20
$11.20
Day's High
$11.20
$11.20
Day's Low
$10.73
$10.73
Volume
22,120
22,120
Avg. Vol
163,769
163,769
52-wk High
$14.30
$14.30
52-wk Low
$2.86
$2.86
About
Insmed Incorporated is a biopharmaceutical company focused on patients suffering with lung diseases through the development and commercialization of targeted inhalation therapies. The Company’s lead candidate ARIKACE, is engineered to deliver anti-infective directly to the site of lung infections for at least two identified... (more)
Overall
| Beta: | -0.14 |
| Market Cap (Mil.): | $420.66 |
| Shares Outstanding (Mil.): | 38.03 |
| Dividend: | -- |
| Yield (%): | -- |
Financials
| INSM.OQ | Industry | Sector | |
|---|---|---|---|
| P/E (TTM): | -- | 47.13 | 37.76 |
| EPS (TTM): | -1.69 | -- | -- |
| ROI: | -38.28 | -2.58 | 18.76 |
| ROE: | -40.90 | -2.66 | 19.59 |
UPDATE 2-Insmed's lung infection drug fares no better than rival, shares fall
* Drug shows smaller improvement in lung capacity vs rival
Insmed's lung infection drug succeeds in late-stage trial
July 1 - Insmed Inc said a late-stage trial of its experimental lung infection drug showed the therapy was as effective as another approved treatment.
Competitors
| Price | Change | |
|---|---|---|
| Novartis AG (NOVN.VX) | CHF66.60 | +0.35 |
| Bayer AG (BAYGn.DE) | €89.10 | +1.75 |
| Bayer AG (BAYE.F) | -- | -- |
| Gilead Sciences, Inc. (GILD.OQ) | $61.35 | -0.10 |
| Forest Laboratories, Inc. (FRX.N) | $44.40 | +0.84 |
| Vertex Pharmaceuticals Incorporated (VRTX.OQ) | $81.19 | +1.39 |
| Aradigm Corporation (ARDM.OB) | $0.19 | +0.01 |
Earnings vs.
Estimates
Analyst Research Reports
| Report Title | Price |
|---|---|
|
Provider: ValuEngine, Inc.
|
$25.00
|
|
Provider: S&P Capital IQ Quantitative Report
|
$69.00
|
|
Provider: Thomson Reuters Stock Report
|
$25.00
|
|
Provider: Pechala's Reports
|
$15.00
|
|
Provider: Reuters Investment Profile
|
$20.00
|
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

